Search results for "Catheter"

showing 10 items of 482 documents

Choosing the nephrostomy size after percutaneous nephrolithotomy.

2011

Purpose: To evaluate the effect of nephrostomy tube size on perioperative outcomes of percutaneous nephrolithtotmy (PCNL). Methods: Forty-five well-matched patients with normal renal function were prospectively divided in two nonrandomized groups after uneventful PCNL (to receive either a 22-Fr, group 1 (n = 24 pts), or a 12-Fr nephrostomy tube, group 2 (n = 21 pts)). In all a balloon nephrostomy catheter with detachable funnel (Rüsch Teleflex, Germany) was used. A Visual Analogue Scale (VAS) for measuring the pain was administered 8 and 24 h after the procedure. Postoperative analgesics use (Ketoralac Tromethamine 30 mg), pre- and postoperative Hb, renal function and urinary leaks were reg…

NephrologyAdultMalePostoperative resultmedicine.medical_specialtyPercutaneousUrologymedicine.medical_treatmentUrologyNephrostomy tubeBlood Loss SurgicalPainPCNLSettore MED/24 - UrologiaKidney CalculiRetrospective StudieInternal medicineNephrostomy PercutaneouPostoperative resultsMedicineHumansPercutaneous nephrolithotomyNephrostomy PercutaneousPain MeasurementRetrospective Studiesbusiness.industryPerioperativeLength of StayMiddle AgedSurgeryTreatment OutcomeNephrostomy catheter sizeNephrostomyFemalebusinessHumanWorld journal of urology
researchProduct

Bloqueo interescalénico guiado por ecografía en un paciente con alteraciones anatómicas de la región supraclavicular secundarias a radioterapia y cir…

2011

Regional blocks can be difficult in surgical patients with certain superficial anatomical abnormalities. Such blocks may be possible, however, under ultrasound guidance. We report a case in which a man with a fractured right humerus required an ultrasound-guided interscalene brachial plexus block. Secondary to radiotherapy, the patient had right cervical and facial abnormalities that had altered the location of external anatomical landmarks. We describe the approach used to insert the catheter and the exploration of the region by ultrasound. Nerve stimulation was not used to avoid painful contractions. Analgesia was excellent during surgery and over the following 24 hours.

Nerve stimulationbusiness.industryInterscalene brachial plexus blockUltrasoundAnatomyCritical Care and Intensive Care MedicineUltrasound guidanceCatheterAnesthesiology and Pain MedicineMedicineRight humerusbusinessBrachial plexusSurgical patientsRevista Española de Anestesiología y Reanimación
researchProduct

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

2021

European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

ORAL ANTICOAGULANT-THERAPYmedicine.medical_specialtyELASTIC COMPRESSION STOCKINGSMEDLINEED AMERICAN-COLLEGEInferior vena cavaCATHETER-DIRECTED THROMBOLYSISBlood vessel prosthesisdeep-vein-thrombosisHeparin-induced thrombocytopeniamedicineYoung adultUPPER EXTREMITY DEEPbusiness.industryINFERIOR VENA-CAVAHEPARIN-INDUCED-THROMBOCYTOPENIAsilent pulmonary-embolismMOLECULAR-WEIGHT HEPARINVascular surgerymedicine.diseaseSurgeryClinical PracticeVenous thrombosismedicine.veinSurgeryCardiology and Cardiovascular MedicinebusinessEuropean Journal of Vascular and Endovascular Surgery
researchProduct

Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.

2017

The European Association for the Study of the Liver Hepatocellular Carcinoma (HCC) international meeting held in Geneva in February 2017 focused on the state of the art of HCC management, from diagnosis to treatment and the potential development of clinical research in this field. This report reviews some of the most interesting topics discussed at the meeting such as the role of hepatitis C viral infection treatment with direct-acting antivirals in enhancing HCC risk, current prognostic systems, early diagnosis techniques, curative therapies for early HCC and the systemic treatments for advanced disease with a look into future perspectives.

OncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsHepacivirusGastroenterologyAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdvanced diseaseHumansNeoplasm StagingHepatitis c viralgeographyClinical Trials as TopicSummitgeography.geographical_feature_categorybusiness.industryLiver NeoplasmsGeneral MedicineCongresses as TopicHepatitis C Chronicmedicine.diseasePrognosisCombined Modality Therapydigestive system diseasesClinical researchOncologyLiver030220 oncology & carcinogenesisHepatocellular carcinomaEarly hccCatheter AblationDisease Progression030211 gastroenterology & hepatologybusinessSwitzerlandFuture oncology (London, England)
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

2010

International audience; Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease, resulting in increased local drug concentrations. Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy. The patient was treated with a combination of gemcitabine and oxaliplatin using HAI. The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI. The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed…

OncologyMale[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/SurgeryOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCase ReportDeoxycytidineMetastasischemistry.chemical_compound0302 clinical medicineHepatic ArteryAntineoplastic Combined Chemotherapy Protocols[ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery0303 health sciencesLiver NeoplasmsGastroenterologyvirus diseasesGeneral MedicineMiddle AgedMagnetic Resonance Imaging3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsCatheter AblationAdenocarcinomaDeoxycytidinemedicine.drugmedicine.medical_specialtyanimal structures[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryAdenocarcinoma03 medical and health sciencesHepatic arterial infusionInternal medicinemedicineHumansInfusions Intra-Arterial030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseGemcitabineGemcitabineOxaliplatinchemistrybusinessTomography X-Ray Computed
researchProduct

Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma

2013

Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the canc…

OncologySorafenibmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationInternal medicineHepatectomyHumansMedicineChemoembolization TherapeuticPrecision MedicineEarly Detection of CancerNeoplasm StagingHepatologybusiness.industryClinical study designLiver NeoplasmsGastroenterologymedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationClinical trialTransplantationTreatment OutcomeHepatocellular carcinomaCatheter AblationLiver functionPersonalized medicinebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy

1999

Thromboembolism is a severe and frequent problem in gynecologic malignancy. The average DVT incidence during chemotherapy of 5% might represent the lower range of incidence because < 55% of thrombotic complication manifest clinical signs. However, it seems likely that in addition to chemotherapy other risk factors such as menopausal status, BMI of patients, or type of preceding surgery must coincide before thrombosis manifests. While monitoring of patients using sophisticated coagulation tests did not identify patients' risk for DVT during chemotherapy, an evaluation of the coagulation status before initiating chemotherapy is recommended. Patients with a venous access device (e.g., indwelli…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)HematologyGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseThrombosis03 medical and health sciencesGynecologic malignancy0302 clinical medicinePort (medical)030220 oncology & carcinogenesisInternal medicinemedicineCoagulation testingcardiovascular diseasesbusinessCentral venous catheterThrombosis preventionClinical and Applied Thrombosis/Hemostasis
researchProduct

Prognostic value of the ratio between prothesis area and indexed annulus area measured by multiSlice-CT for transcatheter aortic valve implantation p…

2016

Background Postprocedural aortic regurgitations following transcatheter aortic valve implantation (TAVI) procedures remain an is- sue. Benefit of oversizing strategies to prevent them isn’t well established. We compared different level of oversizing in our cohort of con- secutive patients to address if severe oversizing compared to normal sizing had an impact on post-procedural outcomes. Methods From January 2010 to August 2013, consecutive patients were referred for TAVI with preoperative Multislice-CT (MSCT) and the procedures were achieved using Edwards Sapien® or Corevalve devices®. Retrospectively, according to pre-procedural MSCT and the valve size, pa- tients were classified into thr…

OversizingTranscatheter aortic valve implantationAortic regurgitation; Aortic valve stenosis; Multislice-CT; Oversizing; Transcatheter aortic valve implantationSymposium: Transcatheter aortic valve implantationAortic valve stenosiAortic regurgitationAortic valve stenosisMultislice-CT
researchProduct